Development of the first geldanamycin-based HSP90 degraders

Despite the early clinical promise, adverse events such as acquired resistance and dose-limiting toxicities have barred the widespread use of HSP90 inhibitors as anticancer drugs. A new approach involving proteolysis-targeting chimeras (PROTACs) to degrade the protein instead of inhibiting it may ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurnig, Silas, Vogt, Melina, Hogenkamp, Julian, Dienstbier, Niklas, Borkhardt, Arndt, Bhatia, Sanil, Hansen, Finn K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336212/
https://www.ncbi.nlm.nih.gov/pubmed/37448856
http://dx.doi.org/10.3389/fchem.2023.1219883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336212/
https://www.ncbi.nlm.nih.gov/pubmed/37448856
http://dx.doi.org/10.3389/fchem.2023.1219883

Ejemplares similares